Pancreatic Neuroendocrine Tumor — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for pancreatic neuroendocrine tumor. 4 active patents protecting 1 drugs from 1+ originators. First major cliff: 2028. Daily refresh.

1
Approved drugs
4
Active US patents
70/100
Avg vulnerability
$600M
Annual revenue covered

Originators in Pancreatic Neuroendocrine Tumor

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Novartis 4 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating pancreatic neuroendocrine tumor. Each bar = one year. Y-axis scaled to peak year (4 patents).

4
28

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Afinitor
everolimus
 Novartis 4 70 $600M 2028-07-01

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9006224 Afinitor method of use 75 2028-07-01
9006224 Afinitor method of use 75 2028-07-01
9006224 Afinitor method of use 75 2028-07-01
9006224 Afinitor method of use 75 2028-07-01

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9006224 Afinitor method of use 75 2028-07-01
9006224 Afinitor method of use 75 2028-07-01
9006224 Afinitor method of use 75 2028-07-01
9006224 Afinitor method of use 75 2028-07-01

Related